Ali Bagheri, MD
Hospitalist · Dallas, TXNPI 1265469522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AOP Health US, LLC$2K
- Johnson & Johnson$2K
- AstraZeneca$896
- Ferring Pharmaceuticals Inc.$744
- Pfizer$609
- Boehringer Ingelheim$601
- plus $4K from 24 others
What the payments were for
- Travel & lodging$130%
- Food & beverage$11,36299%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AOP Health US, LLC | 3 | $2,370 |
| Johnson & Johnson | 80 | $1,842 |
| AstraZeneca(2 entities) | 41 | $896 |
| Ferring Pharmaceuticals Inc. | 21 | $744 |
| Pfizer | 26 | $609 |
| Boehringer Ingelheim | 28 | $601 |
| E.r. Squibb & Sons, L.L.C. | 32 | $563 |
| Merck | 7 | $502 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $494 |
| Astellas Pharma US Inc | 21 | $455 |
| Shionogi Inc | 19 | $406 |
| Novartis | 6 | $268 |
| CSL Behring | 10 | $268 |
| Vifor Pharma, Inc. | 10 | $202 |
| Gilead | 9 | $202 |
| Aimmune Therapeutics, Inc. | 6 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $146 |
| AbbVie | 5 | $142 |
| Biogen | 1 | $123 |
| Orthofix Medical, Inc. | 1 | $108 |
| Paratek Pharmaceuticals, Inc. | 5 | $95 |
| Titan Spine, LLC | 1 | $57 |
| Cumberland Pharmaceuticals, Inc. | 3 | $55 |
| Vertex | 2 | $50 |
| Novo Nordisk | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Seaspine Orthopedics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,454 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hospitalist in Dallas
- Weiyi TanDallas$30K
- Radha YalamanchiliDallas$6K
- Toby MathewDallas$5K
- Apurva YeluruDallas$5K
- Jaini SutariaDallas$4K
- Theo SotteroDallas$4K
- Neeraj KalraDallas$3K
- Mahmoud ElsayedDallas$2K
- Kenechukwu EnekebeCorpus Christi$311K
- Ryan NealHouston$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.